for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd

600332.SS

Latest Trade

36.63CNY

Change

0.34(+0.94%)

Volume

7,395,957

Today's Range

36.05

 - 

36.68

52 Week Range

31.66

 - 

45.88

As of on the Shanghai Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
36.29
Open
36.27
Volume
7,395,957
3M AVG Volume
210.30
Today's High
36.68
Today's Low
36.05
52 Week High
45.88
52 Week Low
31.66
Shares Out (MIL)
1,625.79
Market Cap (MIL)
57,056.94
Forward P/E
16.98
Dividend (Yield %)
1.16

Next Event

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Annual Shareholders Meeting

Latest Developments

更多

Guangzhou Baiyunshan Plans Spin Off Guangzhou Unit For Hong Kong Listing

Guangzhou Baiyunshan Pharmaceutical's H1 Net Profit Down 2.7% Y/Y

Lock-Up Period For Guangzhou Baiyunshan's 334.7 Million A-Shares To End

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited is engaged in the pharmaceutical and healthcare industry. The Company's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The Company's Great South TCM includes research, development, manufacturing and sales for Chinese and western medicine, chemical raw medicine, natural drug, biological medicine and intermediates of chemical raw medicine. The Company's Great Health segment includes research, development, manufacturing and sales for the products of Great Health. The Company's Great Commerce segment includes wholesale, retail, import and export for western medicine, Chinese medicine and medical apparatus and instruments. The Company has an antibiotic production chain ranging from raw material medicine to preparation, with products covering commonly used antibiotics. It is engaged in the research and development (R&D), and manufacturing of beverage and food, among others.

Industry

Biotechnology & Drugs

Contact Info

No. 45 Shamian North Street

Liwan District

+86.20.66281219

http://www.gybys.com.cn/

Executive Leadership

Chuyuan Li

Chairman of the Board, Executive Director

Ning Cheng

Vice Chairman of the Board, Executive Director

Hong Li

General Manager, Executive Director

Changhai Wu

Executive Deputy General Manager, Executive Director

Chunbo Zhang

Deputy General Manager, Executive Director

Key Stats

2.25 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

20.0K

2017

21.0K

2018

42.2K

2019(E)

63.6K
EPS (CNY)

2016

0.928

2017

1.268

2018

2.120

2019(E)

2.157
Price To Earnings (TTM)
17.67
Price To Sales (TTM)
0.94
Price To Book (MRQ)
2.53
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
45.77
LT Debt To Equity (MRQ)
2.59
Return on Investment (TTM)
14.89
Return on Equity (TTM)
7.00

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up